Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 8;59(23):10411-10434.
doi: 10.1021/acs.jmedchem.6b00669. Epub 2016 Sep 27.

Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases

Robert B Cameron  1   2 , Craig C Beeson  1 , Rick G Schnellmann  1   2
Affiliations
Review

Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases

Robert B Cameron et al. J Med Chem. .

Abstract

Mitochondria have various roles in cellular metabolism and homeostasis. Because mitochondrial dysfunction is associated with many acute and chronic degenerative diseases, mitochondrial biogenesis (MB) is a therapeutic target for treating such diseases. Here, we review the role of mitochondrial dysfunction in acute and chronic degenerative diseases and the cellular signaling pathways by which MB is induced. We then review existing work describing the development and application of drugs that induce MB in vitro and in vivo. In particular, we discuss natural products and modulators of transcription factors, kinases, cyclic nucleotides, and G protein-coupled receptors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multiple insults converge upon the mitochondria, leading to mitochondrial dysfunction and subsequent organ injury and disease.
Figure 2
Figure 2
PGC-1α integrates extracellular and cytosolic signaling inputs to selectively upregulate mitochondrial biogenesis.
Figure 3
Figure 3
Naturally occurring polyphenols capable of inducing MB.
Figure 4
Figure 4
Thiazolidinedione inducers of MB.
Figure 5
Figure 5
Estrogen inducers of MB.
Figure 6
Figure 6
Activators of SIRT1 that induce MB.
Figure 7
Figure 7
Kinase modulators that induce MB.
Figure 8
Figure 8
Activators and stimulators of the NO/cGMP pathway.
Figure 9
Figure 9
Phosphodiesterase (PDE) inhibitors associated with MB.
Figure 10
Figure 10
Cannabinoid-1 Receptor antagonists.
Figure 11
Figure 11
5-Hydroxytryptamine receptor modulators that induce MB.
Figure 12
Figure 12
Beta adrenergic receptor modulators tested for the induction of MB.
See this image and copyright information in PMC

References

    1. Whitaker RM, Corum D, Beeson CC, Schnellmann RG. Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases. Annu Rev Pharmacol Toxicol. 2016;56:229–249. - PubMed
    1. Nunnari J, Suomalainen A. Mitochondria: In Sickness and in Health. Cell. 2012;148(6):1145–1159. - PMC - PubMed
    1. Lane RK, Hilsabeck T, Rea SL. The Role of Mitochondrial Dysfunction in Age-Related Diseases. Biochim Biophys Acta. 2015;1847(11):1387–1400. - PMC - PubMed
    1. Hafizi Abu Bakar M, Kian Kai C, Wan Hassan WN, Sarmidi MR, Yaakob H, Zaman Huri H. Mitochondrial Dysfunction as a Central Event for Mechanisms Underlying Insulin Resistance: The Roles of Long Chain Fatty Acids. Diabetes Metab Res Rev. 2015;31(5):453–475. - PubMed
    1. Walters JW, Amos D, Ray K, Santanam N. Mitochondrial Redox Status as a Target for Cardiovascular Disease. Curr Opin Pharmacol. 2016;27:50–55. - PMC - PubMed

Publication types

Substances